Treatment of pulmonary hypertension in interstitial lung disease: Do not throw out the baby with the bath water

European Respiratory Journal

Volumn 41, Issue 4, 2013, Pages 781-783

  Cottin, Vincent ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; CARBON MONOXIDE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MACITENTAN; NINTEDANIB; PIRFENIDONE; PROSTACYCLIN; RIOCIGUAT; SILDENAFIL;

ARTERIAL OXYGEN SATURATION; CARDIOPULMONARY FUNCTION; CARDIOPULMONARY HEMODYNAMICS; COMORBIDITY; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FIBROSING ALVEOLITIS; HEART CATHETERIZATION; HUMAN; HYPOXEMIA; HYPOXIC LUNG VASOCONSTRICTION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG EDEMA; LUNG FIBROSIS; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; OXYGEN CONSUMPTION; OXYGEN THERAPY; PANCYTOPENIA; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; SARCOIDOSIS; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

FEMALE; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MALE; PYRAZOLES; PYRIMIDINES;

EID: 84875830505     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00024113     Document Type: Editorial

References (32)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
2. Nathan SD, Cottin V. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Eur Respir Monogr 2012; 57: 148-160.
3. Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
4. Le Pavec J, Lorillon G, Jais X, et al. Pulmonary Langerhans cell histiocytosis associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142: 1150-1157.
5. Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39: 1520-1533.
6. Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012; 40: 630-640.
7. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
8. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
9. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752.
10. Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30: 715-721.
11. Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101: 2153-2159.
12. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102: 1305-1310.
13. Glaser S, Noga O, Koch B, et al. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med 2009; 103: 317-324.
14. Minai OA, Santacruz JF, Alster JM, et al. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med 2012; 106: 1613-1621.
15. Kimura A, TaniguchiH, Kondoh Y, et al. Pulmonary hypertension as a prognostic indicator at initial evaluation in idiopathic pulmonary fibrosis. Respiration 2012 [in press DOI: 10.1159/000345221].
16. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131: 897-899.
17. Sanchez O, Sitbon O, Jais X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
18. Gluskowski J, Hawrylkiewicz I, Zych D, et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3: 403-407.
19. Farkas L, Gauldie J, Voelkel NF, et al. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 2011; 45: 1-15.
20. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008; 31: 1357-1367.
21. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
22. Colombat M, Mal H, Groussard O, et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38: 60-65.
23. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628.
24. Han MK, Bach DS, Hagan P, et al. Sildenafil preserves exercise capacity in IPF patients with right ventricular dysfunction. Chest 2013 [in press DOI: 10.1378/chest.12-1594].
25. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75-81.
26. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
27. Gunther A, Enke B, Markart P, et al. Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur Respir J 2007; 29: 713-719.
28. Courcier S, Paccioni J-P. Lettre aux professionnels de sante. VOLIBRIS1 (ambrisentan) ne doit pas être utilisé chez les patients atteints d'une fibrose pulmonaire idiopathique. Saint Denis/Paris, ANSM (Agence Nationale de Se'curité du Me'dicament et des Produits de Santé), 2012. Available from: http://ansm.sante.fr/var/ansm-site/storage/original/application/ 1f5283f43069ea39-c44ae6a1952586d8.pdf
29. Hoeper MM, Halank M, Wilkens H, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013; 41: 853-860.
30. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36: 792-799.
31. Vancheri C, du Bois RM. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013; 41: 262-269.
32. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France. Results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.